Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer
Advanced Science · 2026-11 · 13 (62)
DOI: 10.1002/advs.77249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.08.2026. Verfasst von Bo Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Department of Medical Oncology, Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Scien…. Hauptthemen laut MEDLINE: Paclitaxel, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, Anhui Provincial Hospital, Health Research Program of Anhui.
Abstract (Originalsprache)
Drug resistance in solid tumors has emerged as a critical challenge, with limited effective therapeutic options available. In this study, we find that chemotherapy induces an increased tumor neoantigens burden (TNB) in breast cancer patients and both non‐resistant and chemo‐resistant triple‐negative breast cancer 4T1 tumor‐bearing mice. Consistently, proteomic analysis reveals that tumor antigens derived from in vitro chemotherapy‐treated paclitaxel (PTX)‐resistant 4T1 cells (chemo‐rAg) are enriched in damage‐associated molecular patterns and neoantigens, highlighting their potential to elicit antitumor immunity against chemo‐resistant tumors. Based on these findings, we utilize the feature of PTX resistance and develop a nanovaccine incorporating chemo‐rAg and a prodrug of a toll‐like receptor 7 (TLR7) agonist. In preclinical mouse models, the nanovaccine effectively suppresses PTX‐resistant 4T1 tumor growth, and it also reverses the innate resistance of immune checkpoint inhibitors. Notably, the therapeutic benefit of the nanovaccine is augmented by chemotherapy, which facilitates in situ release of tumor antigens. These results suggest that a chemo‐rAg‐based nanovaccine represents a promising strategy based on the ′like cures like' principle to overcome drug resistance by utilizing the characteristic of the drug resistance itself.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Department of Medical Oncology, Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei…
- Department of Bio-X Interdisciplinary Science at Hefei National Laboratory (HFNL) for Physical Science at the Microscale, University of Science and Technology of China, Hefei, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- School of Chemistry and Materials Science, University of Science and Technology of China, Hefei, China.
- State Key Laboratory of Immune Response and Immunotherapy, Center for Advanced Interdisciplinary Science & Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei…
ORCID-Profile: Yuanzeng Min
Förderung
- National Nature Science Foundation of China
- Anhui Provincial Hospital
- Health Research Program of Anhui
- The Strategic Priority Research Program, the Chinese Academy of Sciences
- the Institute of Health and Medicine, Hefei Comprehensive National Science Center
- the Natural Science Foundation of China
Zitieren
APA
Chen, B., Wang, Y., Li, T., Guo, C., Xie, Z., Zhang, Z., Han, X., Wang, W., Wang, J., Ma, X., & Min, Y. (2026). Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer. Advanced Science, 13(62). https://doi.org/10.1002/advs.77249
Vancouver
Chen B, Wang Y, Li T, Guo C, Xie Z, Zhang Z, et al. Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer. Advanced Science. 2026;13(62). doi:10.1002/advs.77249
BibTeX
@article{Chen2026,
author = {Chen, Bo and Wang, Yangyi and Li, Tingting and Guo, Changqing and Xie, Zhe and Zhang, Zhixian and Han, Xinghua and Wang, Wei and Wang, Jian and Ma, Xiaopeng and Min, Yuanzeng},
title = {Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {62},
doi = {10.1002/advs.77249}
}
EUVIMED